C12Y 302/01022
Alpha-galactosidase
Official title: Alpha-galactosidase (3.2.1.22)
C12Y302/01022 (Alpha-galactosidase) appears on 240 US grants and 397 published applications in this corpus.
Search patents in C12Y- Granted patents
- 240
- Published applications
- 397
- Assignees
- 168
- Inventors
- 572
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 2 |
| 2002 | 6 | 10 |
| 2003 | 3 | 11 |
| 2004 | 3 | 11 |
| 2005 | 4 | 4 |
| 2006 | 2 | 6 |
| 2007 | 2 | 4 |
| 2008 | 1 | 4 |
| 2009 | 5 | 6 |
| 2010 | 4 | 10 |
| 2011 | 5 | 13 |
| 2012 | 5 | 11 |
| 2013 | 8 | 24 |
| 2014 | 15 | 20 |
| 2015 | 11 | 18 |
| 2016 | 13 | 22 |
| 2017 | 12 | 16 |
| 2018 | 13 | 17 |
| 2019 | 18 | 29 |
| 2020 | 14 | 27 |
| 2021 | 21 | 20 |
| 2022 | 12 | 34 |
| 2023 | 13 | 21 |
| 2024 | 16 | 22 |
| 2025 | 16 | 26 |
| 2026 | 6 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Digital microbiology15 Sep 2026US 12,735,735 B2Bio-Rad Europe GmbH
- Liposomes and its use for enzyme delivery28 Jul 2026US 12,691,067 B2Consejo Superior De Investigaciones Cientificas (Csic)
- Compositions, devices, and methods for treating Fabry disease9 Jun 2026US 12,649,930 B2Sigilon Therapeutics, Inc.
- Compositions for the treatment of Fabry disease19 May 2026US 12,630,839 B2Sangamo Therapeutics, Inc.
- Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use3 Mar 2026US 12,565,643 B2The Medical College of Wisconsin, Inc.
- Improved pea or faba bean proteins24 Sep 2026US 2026/0283192 A1Roquette Freres
- Folic acid supplementation for treatment of fabry disease24 Sep 2026US 2026/0284057 A1The Research Foundation for Mental Hygiene, Inc.
- Compositions and methods for gene therapies24 Sep 2026US 2026/0286389 A1Exegenesis Bio Co.
- Recombinant adeno-associated viral vector for gene delivery3 Sep 2026US 2026/0258445 A1Abeona Therapeutics Inc.
- Glucosylceramide synthase inhibitors18 Jun 2026US 2026/0167645 A1Genzyme Corporation
Most cited
By later US patents
- mRNA for use in treatment of human genetic diseases131US 8,853,377 B2Shire Human Genetic Therapies, Inc. · 2014
- Production of lysosomal enzymes in plant-based expression systems117US 5,929,304 ACroptech Development Corporation · 1999
- Tranfected human cells expressing human .alpha.-galactosidase A protein114US 6,083,725 ATranskaryotic Therapies, Inc. · 2000
- Cloning and expression of biologically active .alpha.-galactosidase A as a fusion protein85US 5,580,757 AMount Sinai School of Medicine of the City University of New York · 1996
- Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases78US 9,249,424 B2HealthPartners Research & Education · 2016